Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business
Aurobindo’s U.S. formulation business is witnessing price erosion, which is impacting the revenue and margin. However, value unlocking in...
438 Views
India Equity Derivatives - The Tail Wags the Dog
On April 22, the National Stock Exchange of India (NSE) published a list of 34 stocks that would be excluded from the Futures and Options segment...
738 Views